RKDA Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 6.69%, SMA50 -15.04%, SMA200 -45.99%). The stock’s 14-day RSI is 48.44 (neutral), while the ATR of 0.15 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -70.64% below its high and over 27.92% above its low. Average 10-day trading volume of 61.76 thousand shares is below the 3-month average of 2.06 million, indicating normal recent market interest.

Arcadia Biosciences, Inc. generated EPS of -$3.71 over the past year. Five-year average earnings growth is 50.91%. The latest quarter delivered EPS of -$0.38. The next quarter is forecast at $nan. Next year's EPS is expected at $40.93. Arcadia Biosciences, Inc. earnings surprise history is a mixed track record. The quarter that ended August 13, 2026, missed forecasts by -32.14%. The prior quarter beat by 163.75%. Over the last six quarters, Apple has recorded several small beats. These include -293.88% in May 08, 2025.

Arcadia Biosciences, Inc. has 1.37 million shares outstanding. The public float is 1.36 million shares, elevated short interest at 1.52% of float. This equals 20.62 thousand shares. The short ratio is 1.47 days. Institutional investors hold 16.04% of the float. Insiders own 0.16%. Mandala Agribusiness Co-Investments I Ltd holds 9.08 million shares, Shupp Darby E has 1.16 million shares and BISHOP TERRI C has 1.16 million shares.

Arcadia Biosciences, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.24. This means the shares are trading below this model’s fair value.

The stock is currently mid-range between its 52-week high and low $0.38 and $6.71. With a market capitalization of about $731.26 thousand, Arcadia Biosciences, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.55). Key stats such as the average daily volume over the past year has been around 2.15 million shares, volume is running light vs its 52-week average. Headquartered in Davis, TX, Arcadia Biosciences, Inc. operates in the Basic Materials sector and the Agricultural Inputs industry. Led by CEO Thomas J. Schaefer, the company employs approximately 8 people and listed since May 15, 2015. Arcadia Biosciences, Inc. is a U.S.-based company that provides plant-derived health and well-being products.

Arcadia Biosciences, Inc. trades at a P/E ratio of -0.06, slightly below the S&P 500 average, with a price-to-sales ratio of 0.15 and a price-to-book ratio of 1.01 suggesting the stock is closer to book value. The P/FCF stands at -0.28, also below market averages.

Arcadia Biosciences, Inc. (NASDAQ:RKDA) shares are up 16.16% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Arcadia Biosciences, Inc. trading at a premium to the broader market with a P/E of -0.06. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $11.12, suggesting 2252.94% upside. Our AI forecast model points to short-term weakness (-13.25% over two weeks), a medium-term fall (-59.8% over three months), and a longer-term loss (-85.19% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Arcadia Biosciences, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -13.25%, with price expected at $0.41 by September 18, 2026, within a range of $0.34 to $0.48 3-Month Outlook: Projected fall of -59.8%, reaching $0.19 by December 03, 2026, with a range of $0.09 to $0.28. 1-Year Outlook: Projected loss of -85.19%, with price at $0.07 by September 03, 2027, within a range of $0.00 to $0.05.